-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
April 8, 2021, Shanghai — Takeda China announced that Feizeyou® (icatibant acetate injection) has been officially approved by the National Medical Products Administration for the treatment of heredity in adults, adolescents and children ≥2 years of age Acute onset of angioedema (HAE).
Bradykinin B2 receptor antagonist is an on-demand treatment plan recommended by major international HAE diagnosis and treatment guidelines during acute attacks.
Hereditary angioedema is a rare autosomal dominant genetic disease1.
"Because of the lack of targeted treatment drugs for the acute stage of HAE in China, we can only rely on the infusion of freeze-dried fresh plasma to resolve the edema.
Professor Zhi Yuxiang, Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
A number of phase III clinical studies and a real-world observational study after the market have confirmed that Feizeyou® (icatibant acetate injection) has rapid onset and alleviation of edema in various parts of HAE, and its tolerability and safety are also high.
“Thank you very much for the priority review and approval of relevant government departments, so that Takeda can introduce two innovative treatment products for Chinese HAE patients in just one year, to meet the urgent needs of patients for preventive treatment and emergency treatment, and to protect the health of patients throughout the process.
Mr.
